Compare Kyndryl Holdings Inc (KD) vs 10X Genomics Inc (TXG) Price & Performance

Kyndryl Holdings (KD) trades at $11.88, up 3.76% today, showing recent volatility amid mixed technical signals. The company reported positive net income of $252 million in 2025, marking a significant turnaround from prior losses, though revenue has declined from $18.3B in 2022 to $15.1B. Recent news highlights Kyndryl's strategic focus on AI, including the launch of an innovation lab and acquisition of Healthcare IT Leaders to drive growth.

Outlook remains cautious with analyst consensus leaning Hold (71% of ratings) and a $14.67 price target suggesting moderate upside. Key risks include declining revenue trends and competitive pressures in IT services, while opportunities lie in AI-driven modernization contracts and improved profitability. Investors should weigh the turnaround progress against execution risks in a challenging market.

TXG trades at $77.28, up 1.55% on the day, showing resilience despite a bearish technical signal. The company's fundamentals are improving, with revenue reaching $642.82M in 2025 and net losses narrowing significantly to -$43.54M. Recent news highlights strong demand for its Atera spatial biology platform and a favorable patent verdict. However, valuation metrics like a P/S of 15.99 and EV/EBITDA of 249.22 remain elevated, reflecting high growth expectations.

The outlook is cautiously optimistic. The primary opportunity lies in the commercial success of new platforms like Atera and Sentira driving future profitability. Key risks include the high valuation requiring flawless execution, ongoing losses, and competitive pressures in the life sciences tools sector. Analyst sentiment is mixed, with a near-even split between Buy and Hold ratings and a consensus price target slightly below the current price.